Detailed results of the multinational scientific study conducted
by Massachusetts-based medical equipment manufacturer
Boston Scientific Corporation
) has been recently published in the August issue of the prominent
The primary purpose of this study was to examine the
effectiveness and safety of fully covered self-expanding metal
stents (FCSEMS) in the treatment of biliary obstruction in benign
bile duct strictures patients. It also aimed at evaluating the
frequency and durability of benign biliary strictures in the long
This non-randomized study was conducted at 13 centers in 11
countries across 5 continents, wherein 187 benign bile duct
stricture patients were implanted with Boston Scientific's Fully
Covered WallFlex Biliary RX Stent. The WallFlex Biliary RX Stent
has received CE Mark in Europe for curing biliary strictures
produced by malignant neoplasms as well as for benign biliary
Following extended indwell for up to 12 months, physicians
removed these stents to deduce treatment success of bile duct
The study results revealed 100% success rate of endoscopic
removal of FCSEMS from the 155 patients who received the stents.
Overall, the removal success of FCSEMS after extended indwell and
stricture resolution was achieved for approximately 75% of patients
in this trial.
The stricture resolution rates were 90.1% among patients who
underwent scheduled FCSEMS removal. Moreover, the study results
reflected the cost effectiveness of the FCSEMS treatment and its
ability to potentially reduce the requirement for multiple
sequential Endoscopic Retrograde Cholangiopancreatogram (ERCP)
A follow-up of the patients under this study will be done over
five years to determine the long-term durability of stricture
resolution after stent removal.
Currently, Boston Scientific is enrolling patients for another
multi-center, prospective, randomized study which will compare
removable, self-expanding metal stents to plastic stents for the
treatment of benign biliary strictures secondary to chronic
Currently, Boston Scientific has a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical products industry include ICU
Medical, Inc. (
), Abaxis, Inc. (
) and Conatus Pharmaceuticals Inc. (
). While ICU Medical sports a Zacks Rank #1 (Strong Buy), Abaxis
and Conatus hold a Zacks Rank #2 (Buy) each.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis
ABAXIS INC (ABAX): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis
CONATUS PHARMA (CNAT): Free Stock Analysis
To read this article on Zacks.com click here.